睡眠病：アフリカトリパノソーマ症（HAT）市場

Report Overview

The report provides an overview of the sleeping sickness market. It analyzes the epidemiology, geographical markets, and market trends. It also highlights the current market for sleeping sickness, and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of sleeping sickness, types of parasites that cause HAT, and its presence in the regions of the world.

Summary:

Human African trypanosomiasis (HAT) is still a problem in many sub-Saharan African nations, especially in areas with poor infrastructure and resources for treatment. Although the disease has been somewhat controlled, work still needs to be done to completely eradicate it, and vigilante measures must be taken to avoid a comeback. The funding from governments, NGOs and pharmaceutical firms for HAT research and development is increasing. Improved diagnostic equipment, therapies, and preventative measures are likely to be the outcome of this.

The tsetse fly spreads this disease in humans by biting and feeding on blood. The Diptera order contains the Glossina vector. Because Glossina are viviparous, both the male and the female can transmit disease. The transmission of parasites is carried out by numerous subgenus flies, including G. palpalis palpalis, G. p. gambiensis, and G. morsitans, which transmits T. b. rhodesiense. For these flies to live, specific temperatures and relative humidity ranges of 50% to 80% are required. The Glossina, however, is categorized as a “bad vector” since the female only produces 10 larvae in her lifetime and because it loses parasites at every blood feeding.

The symptoms of T. b. gambiense and T. b. rhodesiense are frequently the same, although their frequency, severity, and kinetic appearance vary. HAT clinically develops in two stages. In fact, T. b. rhodesiense can result in patient mortality within six months, but T. b. gambiense patients can survive for more than 10 years.

Report Scope:

The market for sleeping disorders will be thoroughly covered in the current report. The epidemiology, geographical markets, and market trends for sleeping sickness are examined in this paper. This study will highlight the present sleeping sickness market and provide a thorough analysis of the market’s competitive landscape.

Report Includes:

• An overview and up-to-date analysis of the global sleeping sickness market
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimate of the actual market size and revenue forecast for the global sleeping sickness market in USD millions, and corresponding market share analysis based on diagnosis type, treatment modality, and geographic region
• In-depth information (facts and figures) pertaining to the market growth drivers, opportunities and challenges, upcoming technologies, future prospects, and regulatory scenarios; and the impacts of COVID-19 and the Russia-Ukraine war on the market
• Discussion of the importance of ESG in sleeping sickness market, including consumer attitudes, impact of ESG factors on company performance, and the ESG practices followed
• Identification of the major stakeholders, and analysis of their company competitive landscape based on news/developments, company financials, competitive strategies, and operational integration
• Company profiles of major players within the industry

Table of Contents
Chapter 1 Introduction
Overview
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Geographic Breakdown
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
History
Distribution Trends
HAT Causing Parasites
Clinical Features of HAT
Diagnosis of HAT
Antibody Detection
Parasite Detection
Future Perspectives
Population Screening
Chapter 4 Sleeping Sickness by Disease Types
Overview
Trypanosoma Brucei Gambiense
Diagnosis of T. b. Gambiense
Trypanosoma Brucei Rhodesiense
Diagnosis of T. b. Rhodesiense
Chapter 5 Sleeping Sickness by Treatments
Overview
Drugs for HAT Treatment
Product Pipeline
Chapter 6 Competitive Landscape
Competitive Analysis
Chapter 7 Company Profiles
BAYER AG
SANOFI
Chapter 8 Appendix: Acronyms

List of Tables
Table 1 : HAT Types and Their Differences
Table 2 : Anti-Trypanosomal Treatment for HAT
Table 3 : Bayer AG: Product Portfolio
Table 4 : Bayer AG: Annual Revenue, 2021 and 2022
Table 5 : Bayer AG: News
Table 6 : Sanofi: Product Portfolio
Table 7 : Sanofi: Annual Revenue, 2021 and 2022
Table 8 : Sanofi: News
Table 9 : Acronyms Used in This Report

List of Figures
Figure 1 : Life Cycle of Human African Trypanosomiasis (HAT)
Figure 2 : Life Cycle of the Trypanosome Parasite
Figure 3 : Bayer AG: Annual Revenue, 2021 and 2022
Figure 4 : Bayer AG: Revenue Shares, by Business Unit, 2022
Figure 5 : Bayer AG: Revenue Shares, by Region, 2022
Figure 6 : Sanofi: Annual Revenue, 2021 and 2022
Figure 7 : Sanofi: Revenue Shares, by Business Unit, 2022
Figure 8 : Sanofi: Revenue Shares, by Region, 2022